EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

Compare

991 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EYPT Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

EyePoint

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EYPT Stock 12 Month Forecast

Average Price Target

$33.80

▲(120.48% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is $33.80 with a high forecast of $43.00 and a low forecast of $23.00. The average price target represents a 120.48% change from the last price of $15.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","44":"$44","14.75":"$14.75","24.5":"$24.5","34.25":"$34.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$43.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,14.75,24.5,34.25,44],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jul<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.29,15.575384615384614,17.86076923076923,20.146153846153844,22.43153846153846,24.716923076923074,27.002307692307692,29.287692307692307,31.573076923076922,33.85846153846154,36.143846153846155,38.42923076923077,40.714615384615385,{"y":43,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.29,14.867692307692307,16.445384615384615,18.02307692307692,19.60076923076923,21.178461538461537,22.756153846153843,24.333846153846153,25.91153846153846,27.489230769230765,29.066923076923075,30.64461538461538,32.22230769230769,{"y":33.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.29,14.036923076923076,14.783846153846152,15.53076923076923,16.277692307692305,17.024615384615384,17.771538461538462,18.518461538461537,19.265384615384615,20.012307692307694,20.75923076923077,21.506153846153847,22.253076923076925,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.76,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.45,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.65,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 52, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 51, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.27,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$43.00

Average Price Target$33.80

Lowest Price Target$23.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Debanjana Chatterjee

JonesTrading

$43

Buy

180.50%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), Cochlear (Other OTC: CHEOF) and Disc Medicine (NASDAQ: IRON)

Graig Suvannavejh

Mizuho Securities

$33

Buy

115.26%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT) and Ocular Therapeutix (NASDAQ: OCUL)

Lisa Walter

RBC Capital

$39

Buy

154.40%

Upside

Reiterated

02/04/26

RBC Capital Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)

Yi Chen

H.C. Wainwright

$23

Buy

50.03%

Upside

Reiterated

01/08/26

EyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target

Unknown Analyst

Citi

Not Ranked

Citi

$31

Buy

102.22%

Upside

Reiterated

12/04/25

Citi Remains a Buy on EyePoint Pharmaceuticals (EYPT)

Tyler Van Buren

TD Cowen

$25→$20

Buy

30.46%

Upside

Reiterated

11/05/25

TD Cowen Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

Greg Harrison

Scotiabank

$18

Buy

17.42%

Upside

Reiterated

08/07/25

Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)

Yatin Suneja

Guggenheim

$68

Buy

343.57%

Upside

Reiterated

08/06/25

With rapid execution in pivotal study enrollment, we reiterate our Buy rating and set a $68 price target.

Tessa Romero

J.P. Morgan

$26

Buy

69.60%

Upside

Reiterated

05/27/25

J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Debanjana Chatterjee

JonesTrading

$43

Buy

180.50%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), Cochlear (Other OTC: CHEOF) and Disc Medicine (NASDAQ: IRON)

Graig Suvannavejh

Mizuho Securities

$33

Buy

115.26%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT) and Ocular Therapeutix (NASDAQ: OCUL)

Lisa Walter

RBC Capital

$39

Buy

154.40%

Upside

Reiterated

02/04/26

RBC Capital Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)

Yi Chen

H.C. Wainwright

$23

Buy

50.03%

Upside

Reiterated

01/08/26

EyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target

Unknown Analyst

Citi

Not Ranked

Citi

$31

Buy

102.22%

Upside

Reiterated

12/04/25

Citi Remains a Buy on EyePoint Pharmaceuticals (EYPT)

Tyler Van Buren

TD Cowen

$25→$20

Buy

30.46%

Upside

Reiterated

11/05/25

TD Cowen Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

Greg Harrison

Scotiabank

$18

Buy

17.42%

Upside

Reiterated

08/07/25

Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)

Yatin Suneja

Guggenheim

$68

Buy

343.57%

Upside

Reiterated

08/06/25

With rapid execution in pivotal study enrollment, we reiterate our Buy rating and set a $68 price target.

Tessa Romero

J.P. Morgan

$26

Buy

69.60%

Upside

Reiterated

05/27/25

J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering EyePoint Pharmaceuticals

3 Months

xxx

Success Rate

13/21 ratings generated profit

Average Return

+15.81%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +15.81% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

9/11 ratings generated profit

Average Return

+30.12%

reiterated a buy rating 4 months ago

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +30.12% per trade.

2 Years

xxx

Success Rate

10/11 ratings generated profit

Average Return

+51.97%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +51.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EYPT Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EYPT has received 16 Buy Ratings, 31 Hold Ratings, and 0 Sell Ratings. EYPT average Analyst price target in the past 3 months is 33.80.

Each month's total comprises the sum of three months' worth of ratings.

EYPT Financial Forecast

EYPT Earnings Forecast

Next quarter’s earnings estimate for EYPT is -$0.75 with a range of -$0.90 to -$0.61. The previous quarter’s EPS was -$0.85. EYPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year EYPT has Performed in-line its overall industry.

EYPT Sales Forecast

Next quarter’s sales forecast for EYPT is $994.00K with a range of $0.00 to $5.00M. The previous quarter’s sales results were $966.00K. EYPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year EYPT has Performed in-line its overall industry.

EYPT Stock Forecast FAQ

What is EYPT’s average 12-month price target, according to analysts?

Based on analyst ratings, EyePoint Pharmaceuticals Inc’s 12-month average price target is 33.80.

What is EYPT’s upside potential, based on the analysts’ average price target?

EyePoint Pharmaceuticals Inc has 120.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EYPT a Buy, Sell or Hold?

EyePoint Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is EyePoint Pharmaceuticals Inc’s price target?

The average price target for EyePoint Pharmaceuticals Inc is 33.80. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $43.00 ,the lowest forecast is $23.00. The average price target represents 120.48% Increase from the current price of $15.33.

What do analysts say about EyePoint Pharmaceuticals Inc?

EyePoint Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of EYPT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

EYPT Analyst Ratings

EYPT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering EyePoint Pharmaceuticals

EYPT Analyst Recommendation Trends

EYPT Financial Forecast

EYPT Earnings Forecast

EYPT Sales Forecast

EYPT Stock Forecast FAQ

Detailed List of Analyst Forecasts